2 completed, 1 terminated. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 2, Terminated 1 |
Follow Clinically Isolated Syndrome: new trials by email Literature Review of Clinically Isolated Syndrome trials Research Report on Clinically Isolated Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Minocycline in MS: Confirmation of Benefit Minocycline 100mg - Multiple Sclerosis, Clinically Isolated Syndrome | Phase 3 | Terminated | University of Calgary | 9 | 2020-01-31 | 2023-03-24 |
| Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX) RNF, Placebo - Multiple Sclerosis, Clinically Isolated Syndrome | Phase 3 | Completed | Merck KGaA, Darmstadt, Germany | 402 | 2008-12-01 | 2017-03-08 |
| A Prospective Study Looking at the Use of Rebif® in Subjects With Clinically Isolated Syndrome Rebif®, No Treatment - Clinically Isolated Syndrome | Phase 3 | Completed | Merck KGaA, Darmstadt, Germany | 35 | 2005-10-01 | 2013-12-27 |
Multiple Sclerosis (2) · cyclopia sequence (1)
Autoimmune Diseases (2) · Autoimmune Diseases of the Nervous System (2) · Demyelinating Autoimmune Diseases, CNS (2) · Demyelinating Diseases (2) · Immune System Diseases (2) · Nervous System Diseases (2)
Interferon beta-1a (2) · Minocycline (1)
Merck KGaA, Darmstadt, Germany (2) · University of Calgary (1)
Canada (3) · Argentina (1) · Austria (1) · Belgium (1) · Bulgaria (1) · Croatia (1) · Czechia (1) · Estonia (1) · Finland (1) · France (1) · Germany (1) · Greece (1) · Israel (1) · Italy (1) · Latvia (1)